Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.57 |
| ▸ | CA2 | P00918 | 6/20 | 0.57 |
| ▸ | CA7 | P43166 | 6/20 | 0.57 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4467804 | 0.87 | CA1 (0.54) | CA1CA2CA7CA13PPARG | |
| SCHEMBL1059121 | 0.86 | CA1 (0.56) | CA1CA2CA7CA13PPARG | |
| SCHEMBL1060727 | 0.81 | CA1 (0.38) | CA1CA2CA7CA13ADORA2A | |
| SCHEMBL1058960 | 0.80 | CA1 (0.71) | CA1CA2CA7CA13PPARG | |
| SCHEMBL27826672 | 0.80 | CA1 (0.38) | CA1CA2CA7CA13ADORA3 | |
| SCHEMBL29594453 | 0.80 | CA1 (0.38) | CA1CA2CA7CA13ADORA3 | |
| SCHEMBL4486521 | 0.79 | CA1 (0.54) | CA1CA2CA7CA13SMN1; SMN2 | |
| SCHEMBL1062896 | 0.78 | CA1 (0.58) | CA1CA2CA7CA13PPARG | |
| SCHEMBL3230594 | 0.77 | CA1 (0.55) | CA1CA2CA7CA13PPARG | |
| SCHEMBL3226387 | 0.77 | LMNA (0.38) | CA1CA2CA7CA13PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4524072-B2 | — | — | 2010-08-11 | — | — | JP | claimed |
| EP-1333833-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-10-24 | — | — | EP | claimed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | claimed |
| EP-1333833-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-08-13 | — | — | EP | claimed |
| WO-2002059083-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| WO-2006104915-A2 | 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006104917-A2 | PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217401-A1 | e.g. 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N''-substituted-N'-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds; CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis | GLAXO GROUP LIMITED (GB) | 2006-09-28 | — | — | US | disclosed |
| US-20050203109-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2005-09-15 | — | — | US | disclosed |
| US-20040209901-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | disclosed |
| EP-1333833-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002059083-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | CA1 4839/4885CA2 4518/4885CA7 4818/4885 |
| US-20060217401-A1 | e.g. 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N''-substituted-N'-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds; CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis | MAPK8, MAPKAPK2, MAPK7 | CA1 4874/4885CA2 4465/4885CA7 3683/4885 |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, RHOXF2 | CA1 4808/4885CA2 4422/4885CA7 4829/4885 |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | CA1 4839/4885CA2 4518/4885CA7 4818/4885 |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | CA1 4839/4885CA2 4518/4885CA7 4818/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | CA1 4839/4885CA2 4518/4885CA7 4818/4885 |
| US-20040209901-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, MAPK7 | CA1 4639/4885CA2 3740/4885CA7 3898/4885 |
| US-20050203109-A1 | Novel Compounds | MAPKAPK2, CREBBP, CDC42BPB | CA1 4694/4885CA2 3847/4885CA7 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.